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Summary. Of the medical staff of our hospital 
217 members at high risk for hepatitis B were im- 
munized with an experimental hepatitis B vaccine 
and anti-HBs titers used to study the influence of 
two dosage schedules, age, and sex on immunogen- 
icity. Participants were 34 years of age (mean; 
range, 20-61); they were divided into two groups 
and vaccinated three times. Group A received 
42 lag HBsAg for each vaccination. Group B re- 
ceived 84 lag for the first and 21 lag for the second 
and third vaccinations. The seroconversion rate 
was 32.7% after the first, 78.8% after the second, 
and 95.7% after the third vaccination. The partici- 
pants who failed to produce anti-HBs titer (3 IU/1; 
n = 9) or whose anti-HBs titers were below 50 IU/1 
(n= 31) were vaccinated a fourth time. Only mild 
side effects of injections were observed in a third 
of all participants, usually in the form of a sore 
arm. 
Between groups A and B there were no signifi- 
cant differences as far as the seroconversion rate 
and anti-HBs titer were concerned. Nonresponders 
plus low-responders accounted for 19%. Female 
participants produced a markedly higher anti-HBs 
titer than males, and the female/male ratio among 
non- and low-responders was 1:2; among nonre- 
sponders, 1:2.5. There was a negative correlation 
of the anti-HBs titer with the age of the partici- 
pants. These results not only have practical conse- 
quences for revaccination policy, but also offer the 
opportunity to further study the genetic regulation 
Abbreviations: anti-HBc = antibody to hepatitis B core antigen ; 
anti-HBe= antibody to hepatitis B e antigen; anti-HBs =anti -  
body to hepatitis B surface antigen; HBsAg=hepatit is  B sur- 
face antigen; IU/1 = international units per liter; MSD = Merck, 
Sharp, and Dohme 
of the immune response to a complex peptide anti- 
gen in man. 
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The studies of Szmuness et al. [21, 22], Maupas 
et al. [12], Crosnier et al. [2, 3], and Reerink- 
Brongers et al. [18] demonstrated the safety and 
efficacy of active immunization against hepatitis 
B in homosexuals, children in Senegal, hemodialy- 
sis unit staff and patients, and volunteers. These 
populations are not only at high risk as far as mor- 
bidity and mortality of the acute illness is con- 
cerned, but also because of chronic viral hepatitis, 
liver cirrhosis, and primary liver cell carcinoma - 
conditions which to date cannot be treated effec- 
tively. 
In Europe, vaccination was especially recom- 
mended for health care personnel because they are 
at a higher risk for hepatitis B than is the normal 
population [4]. A non- or low-responder rate of 
7%-10% was observed in healthy individuals, but 
these terms are not uniformly defined. Thus, many 
questions related to immunogenicity, sex and age 
dependence, and dosage schedule are still open for 
discussion in this particular group of individuals. 
We conducted a trial in high-risk personnel of a 
large medical school hospital using an experimen- 
tal hepatitis B vaccine [24], when commercial prep- 
arations were not yet available in Germany and 
safety was of great concern. We measured anti- 
HBs titers in this trial to investigate aspects of im- 
munogenicity of HBsAg, using two different dos- 
age schedules against age and sex differences. 
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Methods 
Participants 
Trial participants were recruited from high-risk 
settings within our hospital, e.g., surgery, intensive 
care, hemodialysis, anesthesiology (Table 1). Inclu- 
sion criteria were: no history of hepatitis B, nega- 
tive serologic studies for all markers of hepatitis 
B virus infection or the presence of anti-HBs or 
anti-HBc alone, normal transaminase l vels, and 
written informed consent. There were 217 partici- 
pants in the study. The first 110 were assigned to 
group A (see below), the remaining 107 to group B. 
Groups A and B did not show statistically signifi- 
cant differences in terms of numbers, sex, and age 
(Table 2). 
Vaccine 
The experimental vaccine administered in this trial 
consisted of purified 22 nm HBsAg particles ab- 
sorbed onto aluminium hydroxide adjuvant. It was 
passed for clinical trials by the Ethics Committee 
of the Medical Department of the University of 
G6ttingen. Not only potency, but also safety as- 
Table 1. Distribution of trial participants in different high-risk 
areas of our hospital 
Origin of trial participants Number 
Surgery 56 
Internal medicine 47 
Intensive care/dialysis units 33 
Anesthesiology 24 
Oral surgery 17 
Clinical chemistry 10 
Medical students 9 
Radiology 8 
Pathology 7 
Neurology 3 
Other 3 
Table 2. Assignment of participants to vaccination groups A 
and B. There are no significant differences in total number, 
sex, and age in the various groups 
Total Male Female Age (geometric 
(n) (n) (n) mean/range) 
Male Female 
Group A 110 51 59 33/22-47 
Group B 107 58 49 33/21-55 
Total 217 109 108 33/21-55 
30/21-44 
30/2~61 
30/20-61 
pects played an important role in the preparation 
of the vaccine. Preparation and inactivation proce- 
dures were published in detail by Thomssen et al. 
in 1982 and 1983. Briefly, plasma of healthy anti- 
HBe positive chronic HBsAg carriers was used as 
a source of HBsAg. To reduce its theoretically pos- 
sible residual infectivity, pure HBsAg was treated 
with formalin at the high concentration of 1 : 500 
at 37°C for 4 days. Pepsin digestion was not ap- 
plied, but in the batch used in the present study 
more than 99% of antigens were S-gene products 
and only traces of pre-S antigens could be detected 
[24; Gerlich, personal communication]. 
Study Design 
The vaccination included three injections of vac- 
cine, the first two given 1 month apart and the 
third given 5 months after the first vaccination. 
Participants in group A received three injections 
of 42 gg HBsAg, participants in group B received 
84 ~tg for the first and 2t txg HBsAg for the second 
and third injections. Thus, the total dose was iden- 
tical in both groups. 
Adverse effect protocols and blood samples 
were obtained 3 weeks after each injection. The 
serum was tested for HBsAg, anti-HBs titer, anti- 
HBc, and aminotransferases. 
Participants whose anti-HBs titer was below 
50 IU/1 after the third injection were regarded as 
low responders, and they were vaccinated a fourth 
time. 
From 217 participants who were nrolled in the 
study, only six had to be excluded (one in group A, 
five in group B), all of them because of failure 
to appear for control studies. None of these six 
drop-outs had experienced notable side effects. 
Laboratory and Statistical Methods' 
Anti-HBs titers were measured in the laboratory 
of Prof. Thomssen, G6ttingen, by radioimmunoas- 
say using the WHO standard as a reference. Levels 
of at least 3 IU/1 were regarded as positive, and 
defined seroconversion. Tests for HBsAG and 
anti-HBc were performed using commercially 
available radioimmunoassays in the laboratory of 
Prof. Habermehl, Berlin. Additionally, blood sam- 
ples were measured for alanine and aspartate 
aminotransferases using a spectrophotometric pro- 
cedure, according to the optimized standard meth- 
ods of the Deutsche Gesellschaft ffir Klinische 
Chemie, using commercial kits. Statistical signifi- 
cance of differences between means was calculated 
with Student's t-test. 
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Fig. 1. Anti-HBs of all participants in the trial. Geometric 
means of antibody titers were 0 IU/1 (range, 0-6220) after the 
first injection, 30 (0M 450) after the second, and 428 (0-i 37 800) 
after the third injection. The differences were statistically signif- 
icant, P<0.01 
Results 
Immunogenicity and Revaccination 
The vaccine was highly immunogenic. Anti-HBs 
appeared in 32.7% of the vaccine recipients after 
the first, in 78.8% after the second, and in 95.7% 
after the third injection. Nine of 211 participants 
remained seronegative after the third injection and 
were therefore regarded as nonresponders. 
The level of anti-HBs varies among the individ- 
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Fig. 3. Geometric means of anti-HBs after the third injection 
in men and women. In women, the value was 1170 IU/1 (range, 
0-137800); in men, 171 (0-20000). This difference is statisti- 
cally significant (P<0.002). Age distribution is equal in both 
sexes (see Table 2) 
uals over a wide range. After the first injection, 
the geometric mean was 0 IU/I (range, 0-6220), 
after the second injection 30 IU/1 (0-4450), and 
after the third injection 428IU/1 (0-137800) 
(Fig. 1). The differences were statistically signifi- 
cant (P<0.01).  About 75% of the vaccine recipi- 
ents had an anti-HBs titer of >100 IU/1, about 
19% had a titer < 50 IU/1 (Fig. 2). The group of 
non- and low-responders included 40 participants 
(12 females, 28 males), 34 of which were vaccinated 
a fourth time. Three female and six male individ- 
uals were nonresponders (HBsAg titer _< 3 IU/1). 
After the fourth vaccination, six of nine nonre- 
sponders produced anti-HBs. All three remaining 
participants 
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Fig. 2. Ranges of anti-HBs levels. About 75% of the 
participants howed anti-HBs titers > 100 IU/1 after the 
third injection, about 16% showed titers <50 IU/1 
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Fig. 4. Geometric means of anti-HBs after the third injection, 
all participants stratified for age. With increasing age the anti- 
HBs level was lower. In the age group 20-30 years, the mean 
was 895 IU/I (range, 0-137800), in the group 31 40 years, 383 
(0-49950), and this difference is statistically significant (P< 
0.05). There is also a statistically significant difference between 
the age groups 20-30 years and 41-50 years. In the group 41- 
50 years, the geometric mean was 241 IU/1 (0-16480) and in 
the group 51-61 years, 154 (14-292) 
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Fig. 5. Geometric means of anti-HBs, groups A and B. No sig- 
nificant difference after the first and second injection. The mean 
after the third injection for group A was 891 IU/I (range 
0-51790); for group B, 278 (0-137800). This difference is sta- 
tistically significant (P<0.05). A, 42-42-42 gg HBsAg; B, 
84-21-21 HBsAg 
Table 3. Rate of seroconversion (> 3 IU/1) in the 217 trial par- 
ticipants after the first, second, and third dose of HBsAg, strati- 
fied for groups A and B after the first injection (when double 
the dose of HBsAg was given in group B). There is no signifi- 
cant difference in the seroconversion rate between groups A 
and B 
Group Conversion/ Conversion 
immunized 
(n) (%) 
First dose A 33/110 30 
B 38/107 36 
Total 71/217 32.7 
Second dose Total 171/217 78.8 
Third dose Total 202/211 95.7 
nonresponders were males. Twelve revaccinated 
participants remained low-responders. 
No anamnestic responses were observed in six 
participants who were either anti-HBc or anti-HBs 
positive before vaccination. 
Sex 
The level of anti-HBs was dependent on the sex 
of the participants (Fig. 3). In females the geomet- 
ric mean after the third injection was 1 170 IU/1 
(range, 0-137800); in males, only 171 (0-20000). 
This difference was statistically significant (P< 
0.002). No statistically significant differences be- 
tween males and females were found, however, as 
far as the seroconversion rates after the first vacci- 
nation are concerned. The proportion of nonre- 
sponders and low-responders in males and females 
and the response to revaccination is described in 
the previous paragraph. 
Age 
The level of anti-HBs was also dependent on the 
age of the participants (Fig. 4). The younger the 
vaccine recipients were, the higher was the anti- 
HBs titer produced after the third injection. In the 
age group 20-30 years, the geometric mean was 
895 IU/1 anti-HBs (range, 0-137800); in the age 
group 31-40 years, 383 IU/1 (0-49590); in the age 
group 41-50 years, 241 IU/1 (0-16480); and in the 
age group of 51years and older, 154IU/1 
(14-2930). The differences between the age groups 
20-30 years and 31-40 years and 20-30 and 41- 
50 years were statistically significant (P<0.05). 
Higher age groups were too small to achieve statis- 
tical significance, but Fig. 4 clearly shows the trend 
to lower anti-HBs titers in the older age groups. 
692 A. Kr/imer et al. : German Experimental Hepatitis B Vaccine 
Variation of Dosage Schedule 
Compared with group A the higher dose of HBsAg 
in group B did not have an important effect on 
the seroconversion rate after the first injection (Ta- 
ble 3). It was 36% in group B and 30% in group A, 
a difference which was not statistically significant. 
The geometric mean of the anti-HBs titer after the 
third injection in group B was 278 IU/1 (0-51 790) 
and thus significantly (P<0.05) lower than in 
group A with 891 IU/1 (0-137800) (Fig. 5). 
Adverse Effects 
Only minor side effects occurred. Almost 30% of 
the participants complained about soreness of the 
arm at the injection site. Other complaints were: 
rash at the injection site, pruritus and elevated 
body temperature, in a few cases only. All adverse 
effects resolved within 2-4 days. 
Discussion 
Safety aspects played an important part in the 
preparation of the German experimental vaccine 
used in this trial [25]. In order to reduce the theo- 
retically possible residual infectivity, a high forma- 
lin concentration of 1:500 was used for inactiva- 
tion [24]. This procedure for selection and inactiva- 
tion of the experimental vaccine leads to changes 
in antigenicity and immunogenicity of the vaccine, 
which are lower than those of the MSD vaccine 
(HB-Vax). While the geometric mean of anti-HBs 
levels after the third injection was only 428 IU/1 
in our study, it is significantly higher when the 
MSD vaccine is used [28]. This is of practical im- 
portance in view of revaccination policy, since the 
initial anti-HBs titer was shown to predict he loss 
of protection after between 1 and 5 years [11]. As 
far as the seroconversion rates after the third injec- 
tion are concerned, there is no difference between 
the experimental vaccine and the commercially 
available ones [2, 4, 23]. 
In the context of our aim to study aspects of 
immunogenicity of HBsAg (such as genetic regula- 
tion of antibody response), the destruction of part 
of the antigenic epitopes may be of advantage. The 
detection of differences in genetic regulation could 
be facilitated, since it is well known that antibody 
responses are regulated on the single epitope level. 
As a consequence, compared with other studies 
[2, 5, 10, 12, 21], we observe a relatively high per- 
centage (19%) of non- and low-responders and 
their immune system is now being studied. 
It is interesting to note that in six individuals 
with either anti-HBc or anti-HBs positive sera no 
anamnestic response was observed, indicating that 
these "antibodies" were probably not related to 
previous infection with hepatitis B virus. It is thus 
important to immunize such persons. 
One of the initial questions of our study was 
whether a modified immunization schedule with 
a higher first dose of 84 ~tg and lower successive 
doses of 21 gg would result in an earlier serocon- 
version. This was not the case. Seroconversion 
rates after the first injection were similar in 
groups A and B (Table 3). In another study, using 
dosages different from ours, no significant differ- 
ences in the seroconversion rates were observed 
with doses of 40, 20, and 10 gg HBsAg [10]. On 
the other hand, in this latter investigation, the lev- 
els of anti-HBs after the booster injection were 
dose-dependent. A 40-gg HBsAg dose resulted in 
higher anti-HBs titers than the 20- and 10-gg 
doses. This is in agreement with our findings that 
the anti-HBs levels after the third injection are 
lower with the dosage schedule 84-21-21 gg. 
The immune response depended on sex and age 
of the participants. Women acquired significantly 
higher anti-HBs levels, and the older the vaccinees 
were the lower were the anti-HBs titers after the 
booster injection. This was statistically significant 
between the age groups 20-31/31-40 and 
20-30/41-50 years, and Fig. 4 clearly shows this 
trend for the other age groups as well. These find- 
ings are similar to those of other authors [6, 8, 
20, 21, 27], but only one author could demonstrate 
statistical significance [27]. Also, Wildgrube et al. 
[27] found a higher seroconversion rate in females 
and young vaccinees after the first injection, which 
we did not observe. Other studies have failed to 
demonstrate a dependency of the immune response 
on the sex of vaccinated health care workers [5] 
or Senegalese children [12]. 
Nonresponders and low-responders (partici- 
pants who had anti-t-IBs titers below 50 IU/1 after 
the third injection) received a fourth injection. It 
is known that a rapid decline in anti-HBs levels 
occurs within half a year after vaccination [11] and 
only persons with anti-HBs titers of 10 IU/1 or 
higher are judged to be protected against hepatitis 
B. After the fourth injection, six of nine of the 
nonresponders acquired anti-HBs and all the low- 
responders showed a higher anti-HBs level. In ure- 
mic patients with a high proportion of nonre- 
sponders more frequent injections also resulted in 
a higher seroconversion rate [1]. 
Only minor adverse ffects were observed. Al- 
most 30% of the participants complained about 
soreness of the arm at the injection site. Other side 
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effects were a rash at the injection site, pruritus 
and temperature elevations, which were seen in a 
few cases only. Thus it can be concluded that the 
vaccine is safe and the adverse ffects are similar 
to those after application of other vaccine prepara- 
tions [22, 23, 27]. 
Our results and other studies including experi- 
ments in mice [9, 13, 14, 15, 16, 26] suggest hat 
responsiveness to hepatitis B vaccine might be ge- 
netically determined, but a clear marker could not 
yet be elucidated in man. This may in part be due 
to small groups and unsophisticated methodology. 
We have observed a relatively large group of non-/ 
low-responders to HBsAg vaccination who are 
currently being screened for immune markers. This 
and the observed influence of sex and age will not 
only have practical consequences for revaccination 
policy but also offers the possibility to study the 
genetic regulation of an immune response to a 
complex peptide antigen in man. New modalities 
to circumvent a genetically determined low anti- 
body response are already conceivable, such as im- 
munization with pre-S antigens [7, 17], and this 
makes it more desirable to be able to predict the 
types of responders to conventional HBsAg vac- 
cines. 
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